SRXN1

Across TCGA pan-cancer cohorts, SRXN1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRXN1 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SRXN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRXN1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where SRXN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.317	0.709	.003	42	view →
PDAC	OS	Quartile	III,IV	0.346	0.973	.001	33	view →
HNSC	DFS	Tertile	All	1.000	0.900	.006	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.494	0.848	.011	5	view →
GBM	OS	Quartile	All	0.320	0.545	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRXN1–LUAD (DFS)

Open the LUAD breakdown →